Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
View in:
PubMed
subject areas
Adult
Adult
Area Under Curve
Area Under Curve
B-Cell Activating Factor
B-Cell Activating Factor
B-Lymphocyte Subsets
B-Lymphocyte Subsets
Dizziness
Dizziness
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Double-Blind Method
Double-Blind Method
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Headache
Headache
Humans
Humans
Injections, Intravenous
Injections, Intravenous
Injections, Subcutaneous
Injections, Subcutaneous
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Lymphocyte Count
Lymphocyte Count
Male
Male
Metabolic Clearance Rate
Metabolic Clearance Rate
Middle Aged
Middle Aged
Nausea
Nausea
Recombinant Fusion Proteins
Recombinant Fusion Proteins
Treatment Outcome
Treatment Outcome
Young Adult
Young Adult
authors with profiles
Joan Merrill